Oncopeptides AB (LTS:0RN4) Other Current Liabilities : kr35.52 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Other Current Liabilities?

Oncopeptides AB's other current liabilities for the quarter that ended in Mar. 2025 was kr35.52 Mil.

Oncopeptides AB's quarterly other current liabilities declined from Sep. 2024 (kr34.17 Mil) to Dec. 2024 (kr20.70 Mil) but then increased from Dec. 2024 (kr20.70 Mil) to Mar. 2025 (kr35.52 Mil).

Oncopeptides AB's annual other current liabilities declined from Dec. 2022 (kr44.68 Mil) to Dec. 2023 (kr19.02 Mil) but then increased from Dec. 2023 (kr19.02 Mil) to Dec. 2024 (kr20.70 Mil).

Oncopeptides AB Other Current Liabilities Historical Data

The historical data trend for Oncopeptides AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Other Current Liabilities Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Current Liabilities

Get a 7-Day Free Trial

191.60

171.58

44.68

19.02

20.70

Oncopeptides AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Current Liabilities	Get a 7-Day Free Trial															51.75	112.16	34.17	20.70	35.52

Oncopeptides AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Oncopeptides AB Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden OND:Germany

Address

Luntmakargatan 46, Stockholm, SWE, SE-111 37

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and, in particular, multiple myeloma.

Oncopeptides AB Headlines

No Headlines